Comparative Pharmacology
Head-to-head clinical analysis: RAPLON versus RAUDIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAPLON versus RAUDIXIN.
RAPLON vs RAUDIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
Terminal elimination half-life 50-100 hours; clinical context: once-daily dosing achieves steady state in 1-2 weeks.
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Primarily renal (80-90% as unchanged drug), minor biliary/fecal (10-20%).
Category C
Category C
Antihypertensive
Antihypertensive